Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2019
Price : $35 *
At a glance
- Drugs Panitumumab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 08 Mar 2019 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Nov 2016 Planned End Date changed from 31 Dec 2015 to 31 Mar 2018.